

## **Supplementary information**

### **Phlda3 regulates beta cell survival during stress**

Mohammed Bensellam<sup>1,2</sup>, Jeng Yie Chan<sup>1,3</sup>, Kailun Lee<sup>1</sup>, Mugdha V. Joglekar<sup>4</sup>, Anandwardhan A. Hardikar<sup>4</sup>, Thomas Loudovaris<sup>5</sup>, Helen E. Thomas<sup>5,6</sup>, Jean-Christophe Jonas<sup>2</sup> and D. Ross Laybutt<sup>1,3</sup>

<sup>1</sup> Garvan Institute of Medical Research, Sydney, NSW, Australia

<sup>2</sup> Université catholique de Louvain, Institut de recherche expérimentale et clinique, Pôle d'endocrinologie, diabète et nutrition, Brussels, Belgium

<sup>3</sup> St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia

<sup>4</sup> NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia

<sup>5</sup> St Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia

<sup>6</sup> St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria, Australia

#### **Corresponding authors:**

Mohammed Bensellam

Université catholique de Louvain, Institut de recherche expérimentale et clinique, Pôle d'endocrinologie, diabète et nutrition, Brussels, Belgium.

Tel: 32-2-764-9586; Fax: 32-2-764-5532; Email: mohammed.bensellam@uclouvain.be

D. Ross Laybutt

Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW 2010, Australia.

Tel: 61-2-9295-8228; Fax: 61-2-9295-8201; Email: r.laybutt@garvan.org.au

**Supplementary Table 1.** Characteristics of organ donors and islet preparations

Donor	Age	Gender	BMI	Diabetes duration	Diabetes treatment	Comments	Cause of death	Islet purity	Cell viability
N-SVI-014-10	34	M	30,6	-	-	No family history	Prescription drug overdose (28min downtime)	65%	74%
N-SVI-020-10	33	F	31	-	-	No family history	Suicide - Hanging (45min downtime)	80%	ND
N-SVI-032-10	40	F	24,1	-	-	No family history	Hypoxia (35min downtime)	90%	71%
N-SVI-042-10	65	M	36,8	-	-	No family history	Spontaneous subarachnoid hemorrhage	90%	ND
N-SVI-014-14	53	M	30,2	-	-	No family history	Cerebral hypoxia/ischemia (34min downtime)	70%	73%
N-SVI-023-14	61	F	31,9	-	-	No family history	Cerebral infarction (30min downtime)	90%	96%
N-SVI-040-14	39	M	23,9	-	-	Grandfather T2D	Cerebral hypoxia/ischemia (0 min downtime)	95%	83%
N-SVI-011-16	61	M	25,5	-	-	No family history	Intracranial haemorrhage	95%	84%
T2D- SVI-007-11	47	M	30,9	12 years	Diet controlled	Father T2D	Spontaneous subarachnoid hemorrhage	90%	85%
T2D- SVI-001-12	44	M	44,1	Undiagnosed	None	Alcoholic with liver cirrhosis, Father T2D on Dialysis. Not T1D no Autoantibodies	Spontaneous subarachnoid hemorrhage	70%	ND
T2D- SVI-005-14	57	F	24,8	<1 year	Diet/exercise controlled	Father, Uncle, Sister Insulin dependent Diabetics	Spontaneous subarachnoid hemorrhage	90%	ND
T2D- SVI-014-15	40	M	30,4	Undiagnosed	None	Mother T2D Confirmed not T1D no Autoantibodies	Hypoxia secondary to obstructive sleep apnea + community acquired pneumonia vs. meningoencephalitis (35min downtime)	75%	83%
T2D- SVI-010-16	65	M	37,2	15 years	Oral hypoglycemic, DIABEX (Metformin), DIAMICRON (Gliclazide)	Sister T2D	Cerebral infarction (27min downtime)	80%	ND

F: Female, M: Male, N: Non-diabetic, ND: Not determined, T2D: Type 2 diabetes

**Supplementary Table 2.** Characteristics of the three non-diabetic organ donors and their islet preparations

Donor	Age	Gender	BMI	Islet purity	Cell viability
1	62	F	29.3	90%	95%
2	58	M	27.2	80%	90%
3	50	F	28.8	95%	Not done

F: Female, M: Male

**Supplementary Table 3.** Sequences of oligonucleotide primers (5'-3')

Gene symbol	5' Oligonucleotide	3' Oligonucleotide
<i>Cyclophilin (Cypa, Ppia)</i>	TGTGCCAGGGTGGTGA CTTTAC	TGGGAACCGTTTGTGTTTGG
<i>Ddit3 (Chop, Gadd153)</i>	TTCACTACTCTTGACCCTGCGTC	CACTGACCACTCTGTTTCCGTTTC
<i>Dnajc3 (p58<sup>IPK</sup>)</i>	AAGCCCGTGGAAGCCATTAG	GGTCATTTTCATTGTGCTCCTGAG
<i>Fkbp11</i>	ACACGCTCCACATACTACACGG	ATGACTGCTCTTCGCTTCTCTCCC
<i>Gpx1</i>	ACAGTCCACCGTGTATGCCTTC	CTTTCATTCTTGCCATTCTCCTG
<i>Glut2 (Slc2a2)</i>	CATTCTTTGGTGGGTGGC	CCTGAGTGTGTTTGGAGCG
<i>Hmox1 (HO-1, Hsp32)</i>	CCACACAGCACTATGTAAAGCGTC	GTTCCGGAAGGTAAAAAAGCC
<i>Hspa5 (Bip, Grp78)</i>	AGGACAAGAAGGAGGATGTGGG	ACCGAAGGGTCATTCCAAGTG
<i>Hsp90b1 (Grp94)</i>	AAACGGCAACACTTCGGTCAG	GCATCCATCTCTTCTCCCTCATC
<i>Id1</i>	TTGGTCTGTCGGAGCAAAGC	GCAGGTCCCTGATGTAGTCGATTAC
<i>Il1<math>\beta</math></i>	TGTTCTTTGAAGTTGACGGACCC	CCACAGCCACAATGAGTGATACTG
<i>iNos (Nos2)</i>	GCACCTTGGAAGAGGAGCAACTAC	TGCGGCTGGACTTTTCACTC
<i>Ikb<math>\alpha</math> (Nfkbia)</i>	ACCCCTCTACATCTTGCCTGTGAG	CGTTGACATCAGCACCCAAAG
<i>Mafa</i>	CGTCAACGACTTCGACCTGATG	ATCCTCCAGCACCGCTTTTC
<i>p21 (Cdkn1a, Waf1)</i>	CTTGTCGCTGTCTTGCACCTCTG	CTTCAGGGTTTTCTCTTG CAGAAG
<i>Pdia4 (Erp72)</i>	AGTCAAGGTGGTGGTGGGAAAG	TGGGAGCAA AATAGATGGTAGGG
<i>Phlda3</i>	CACATCTACTTCACGCTAGTGACCG	GTTGATTCTTGA ACTTGACCAGGC
<i>Srxn1</i>	TACCAATCGCCGTGCTCATC	AAAGGAATAGTAGTAGTCGCCACCC
<i>Trb3</i>	TCTTCAGCAACTGTGAGAGGACG	TCCAGACATCAGCCGCTTTG
<i>Xbp1</i>	GCAGCAAGTGGTGGATTTGG	AGATGTTCTGGGGAGGTGACAAC



Aliases of gene symbols given in parentheses

Control



 $H_2O_2$  50  $\mu$ M

Preparation 1



PHLDA3



Preparation 2




Preparation 3



### Supplementary Figure 1. PHLDA3 immunostaining in $H_2O_2$ -treated human islets

Human islets from 3 different preparations were cultured in the absence or presence of 50  $\mu$ mol/l  $H_2O_2$  for 24h. At the end of culture, islets were fixed, embedded in paraffin and sections prepared for assessment of PHLDA3 expression. The representative images shown in Fig. 4g are from preparation 1. These images show the upregulation of PHLDA3 immunostaining throughout  $H_2O_2$ -treated islets in both beta and non-beta cells. Scale bar, 50  $\mu$ m.



**Supplementary Figure 2. Effect of *Phlda3* knockdown on hypoxia-induced apoptosis**

MIN6 cells transfected with either control siRNA (si-C) or siRNA against *Phlda3* (si-Ph3) were cultured in the presence of normoxia (20% O<sub>2</sub>; white bars) or hypoxia (1% O<sub>2</sub>; grey bars) for 24h. Changes in apoptosis levels were normalized to DNA content. Data are means±SEM for 3 experiments. \*\*\* $p < 0.001$  vs normoxia. (two-way ANOVA+test of Bonferroni).

